About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, July 31st, 2017

The QualityStocks
Daily Stock List


Tyme Technologies, Inc. (TYME)

OTC Markets Group reported earlier on Tyme Technologies, Inc. (TYME), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Tyme Technologies, Inc. is a clinical-stage pharmaceutical company headquartered in New York, New York. It concentrates on discovering and developing highly targeted cancer therapeutics for a wide assortment of oncology indications. The Company is researching a mechanism that it believes may work alongside the body’s immune system to fight Stage IV Metastatic Cancer. A research and development (R&D) enterprise, Tyme Technologies lists on the OTCQB.

Tyme Technologies focuses on creating medicines that use the body’s immune system to treat diseases. The Company’s R&D efforts are established on a proprietary platform technology, for which Tyme retains worldwide Intellectual Property (IP) and commercial rights. At present, Tyme is conducting a Phase II trial in prostate cancer in addition to continuing collaborations with the Mayo Clinic, Mount Sinai, as well as other institutions.

The Company’s lead program is SM-88. This is a proprietary combination drug product. The design of SM-88 is to penetrate only living cancer cells without toxic effects and without involving healthy body tissue. SM-88 is a novel first-in-class therapy designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death.

Tyme Technologies’ belief is that SM-88 is a first-in-class oncology therapy, which increases the power of the body’s innate defenses to use oxidative stress to kill cancer cells. SM-88 is investigational and undergoing clinical studies to evaluate safety and effectiveness. SM-88 has not been approved by the Food and Drug Administration (FDA).

SM-88 is a combination of a proprietary novel molecule with three currently-marketed drugs generally considered safe for their already approved indications, which are in areas other than cancer treatment. SM-88 is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell.

SM-88 has been used in more than 84 individuals. It has shown a clinical response in 13 cancer types. In its first-in-human trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32 percent of patients alive at the end of the three-year evaluation period without any drug-related serious adverse events.

In June 2017, Tyme Technologies presented (at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago) positive interim data from a continuing Phase Ib/II clinical trial (NCT02796898) evaluating the safety, pharmacokinetics, and efficacy of its investigational therapy candidate, TYME-88, in the treatment of recurrent, non-metastatic prostate cancer.

Results in eight prostate cancer subjects evaluable to date show improvement in the study’s primary endpoints: prevention of radiographically detectable lesions (100 percent); decrease in circulating tumor cells (87.5 percent); stabilization or improvement in PSA doubling time (87.5 percent); delay of subsequent toxic therapy, including ADT or chemotherapy (100 percent); and avoidance of worsening patient reported outcomes (all subjects).

Tyme Technologies, Inc. (TYME), closed Monday's trading session at $4.2501, up 6.25%, on 8,700 volume with 11 trades. The average volume for the last 60 days is 3,395 and the stock's 52-week low/high is $1.01/$6.80.

Spotlight Innovation, Inc. (STLT)

PennyStockLocks, StockRockandRoll, Elite Stock Alerts, Beacon Equity Research, Penny Stock Finder, Stock Preacher, Profitable Trader Authority, Damn Good Penny Picks, OTCtipReporter, Penny Picks, PennyStockScholar, Journal Transcript, SuperStockTips, InvestorSoup, Penny Stock Craze, Stock Commander, TopPennyStockMovers, Ceocast News, and Real Pennies reported on Spotlight Innovation, Inc. (STLT), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Spotlight Innovation, Inc. advances technologies designed to address rare, emerging, and neglected diseases. The Company identifies and acquires rights to innovative and proprietary platform technology candidates. Its focus is on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Spotlight subsidiaries include Celtic Biotech and Caretta Therapeutics, LLC. A pharmaceutical Company, Spotlight Innovation has its corporate headquarters in Urbandale, Iowa.

The Company provides solutions for healthcare-focused companies commercializing healthcare intellectual property (IP). Spotlight will partner with proven market leaders via sale, out-license, or strategic alliance, when commercially significant benchmarks have been reached. Spotlight works to acquire the rights, through acquisition, license, or otherwise, to unique and proprietary Platform Technology Candidates. Moreover, the Company works to provide value-added development capability and funding to realize fast IND approval to begin human clinicals for targeted Platform Technology Candidates.

Spotlight Innovation’s mission is to significantly impact patient health through advancing new platform biotechnologies for cancer and infectious disease. Access to platform technology candidates is attained through its extensive relationships with numerous top academic institutions and other sources. The Company provides value-added development capability and funding to hasten development progress.

Spotlight Innovation has obtained from the Florida State University Research Foundation (FSURF) exclusive global rights to develop and commercialize certain compounds for the treatment of viral infections. This includes the Zika virus infection. In February 2017, Spotlight announced that it entered into a second license agreement with FSURF for the development and commercialization of additional anti-Zika virus compounds.

Spotlight Innovation announced in March of this year that it began Part 2 of a Phase 1 Cancer Trial. It announced that its subsidiary, Celtic Biotech, started Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. ImmunoClin Ltd. is the contract research organization (CRO) overseeing the study conduct. ImmunoClin specializes in clinical development.

Spotlight Innovation recently announced that its subsidiary, Caretta Therapeutics, signed a manufacturing agreement with contract manufacturing organization (CMO) Maitland Labs, LLC (Orlando, Florida) to produce the active pharmaceutical ingredient (API) for Venodol, the Company's first Over-The-Counter (OTC) product for the treatment of chronic pain. Maitland Labs is the second CMO producing Venodol's API on behalf of Caretta Therapeutics. The primary CMO has completed the initial API production run, and commercial production of Venodol is expected to commence shortly. Venodol is a new OTC, non-addictive alternative to opioid and steroidal analgesics tentatively scheduled to be available in the U.S. this summer.

Spotlight also recently announced that it entered into a Sponsored Research Agreement with Brigham and Women's Hospital (BWH) to support research directed by Mr. Kevin Hodgetts, Ph.D., targeted at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Professor Hodgetts is a member of Spotlight Innovation's Scientific Advisory Board. He is also a co-inventor of STL-182, Spotlight Innovation's lead product candidate for SMA.

Spotlight Innovation, Inc. (STLT), closed Monday's trading session at $0.233, down 0.43%, on 1,300 volume with 3 trades. The average volume for the last 60 days is 44,507 and the stock's 52-week low/high is $0.111/$1.75.

Q2Power Technologies, Inc. (QPWR)

StockRockandRoll, Beacon Equity Research, PHUB News, DSR News, PennyStockLocks, Stock Preacher, Penny Stocks Finder, SuperStockTips, InvestorSoup, Penny Stock Craze, and Stock Commander reported earlier on Q2Power Technologies, Inc. (QPWR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Q2Power Technologies, Inc., via its Q2Earth division, is working to become a foremost manufacturer of compost and engineered soils from recycled waste for the agriculture, horticulture, construction, and infrastructure sectors. It is working to build the preeminent compost and soil company in North America, with worldwide growth opportunities. The Company is doing so through a plan of acquisitions, strategic alliances, and organic growth centered on creating and marketing quality beneficial reuse end products. OTCQB-listed, Q2Power Technologies is headquartered in Palm Beach, Florida.

Q2Earth is the operating division of Q2Power Technologies. Q2Power was previously in the business of developing waste fuel-to-power systems based on innovative engine technology. Recently, Q2Power completed the first phase of a bridge financing. This financing will expedite its business plan and operational transition. The Company signed two exclusive term sheets for the acquisition of compost facilities, and has wound-down its prior waste-to-energy research and development (R&D) operations.

Q2Power’s Q2Earth division contributes to restoring soil health through manufacturing the highest quality compost and engineered soils. Q2Earth will grow and optimize operations of acquired and developed compost facilities by making the owners of acquired facilities part of Q2Earth’s success; introducing top management and access to growth capital; and transitioning facilities to concentrate on quality product manufacturing.

Q2Earth will also cross-pollinate best operating practices to boost efficiencies and profitability; expand product selection, differentiation, and distribution channels; as well as build the widest national footprint to service large customers in many sectors.

Q2Power Technologies, by way of its Q2Earth division, has signed a term sheet to acquire Environmental Turnkey Solutions LLC (ETS). ETS is headquartered in Naples, Florida. It is one of the largest green waste hauling and compost manufacturing companies in Florida. ETS provides high quality soils to major customers, which include Scotts Miracle-Gro and Old Castle, with present annualized revenue in excess of $7 million from tipping fees and end product sales.

In addition, Q2Power Technologies, through Q2Earth, signed a Memorandum of Understanding (MOU) with Walker Environmental Group, Inc. Walker Environmental is a Canadian industrials enterprise. Walker provides sustainable waste management solutions, food residuals processing, patented biosolids management technology, and premium soils and mulches, among its varied portfolio. With this MOU, the parties agreed to collaborate over the following 24 months in the acquisition of companies involved in the compost manufacturing and sustainable soils markets.

Last week, Q2Power Technologies announced that it successfully completed a Phase I services contract for Fordstam Limited, the owner of the Chelsea Football Club, United Kingdom (UK). The project included delivery of a feasibility report demonstrating positive results for the beneficial reuse of aggregate materials to be excavated from the team's proposed new stadium construction. Because of the Phase I conclusions, Q2Earth has been awarded a Phase II contract to further explore the economic viability of developing a UK- based soils manufacturing business.

Q2Power Technologies, Inc. (QPWR), closed Monday's trading session at $0.152, up 1.33%, on 71,100 volume with 11 trades. The average volume for the last 60 days is 64,145 and the stock's 52-week low/high is $0.01/$0.20.

North America Frac Sand, Inc. (NAFS)

SMS Penny Picks, eliteotc.com, Wall Street Beauties, WINNINGOTC, PennyStockProfessor, TheNextBigTrade, Stock Commander, Fortune Stock Alerts, PennyPickAlerts, BestDamnPennyStocks, DSR News, and Penny Stock Hub reported earlier on North America Frac Sand, Inc. (NAFS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

North America Frac Sand, Inc. is a development stage company based in Saskatoon, Saskatchewan. It owns renewable land leases with the right to extract frac sand from significant mineral deposits located in the Province of Saskatchewan. The Company has 29,000 acres of leases and lease options 30 kilometers east of Saskatoon. North America Frac Sand lists on the OTC Markets Group’s OTCQB.

Frac Sand is a proppant used in the oil and gas industry as a part of the hydraulic fracturing process - a method to boost flow to the wellhead. North America Frac Sand’s strategy is to attain a significant presence in the frac sand industry through developing a long term, high quality, and secure supply of frac sand for the oil & gas industry in Western Canada and the Northwestern United States.

Concerning frac sand, it must have specific characteristics. These include reaching certain levels of crush resistance, sphericity, and roundness. Thus, it is a relatively rare commodity. North America Frac Sand has established relationships with all the major well service companies. This includes several large oil & gas companies. Furthermore, the Company has government and municipality support.

On September 9, 2015, North America Frac Sand announced the acquisition of North America Frac Sand (CA) Ltd. and its acres of leases. On February 29, 2016, North America Frac Sand announced completion of the due diligence obligatory preceding the decision to close on the acquisition of North America Frac Sand (CA) Ltd. (NAFS-CA).  North America Frac Sand’s short-term intention is to prove out the balance of its major resource. Its long-term intention is to start shipments of frac sand as soon as possible.

In addition, the Company’s strategy is to develop and maximize the mineral deposit under its land and optioned leases, and develop a long-term relationship with well service and oil & gas companies that centers on quality service and product. Additionally, North America Frac Sand’s strategy involves providing a year-round supply of frac sand to customers.

Recently, North America Frac Sand announced that on May 25, 2017, it received its initial "Technical Report" addressing its Eagle Creek Property in Saskatchewan. The Technical Report was prepared in accordance with the requirements of National Instrument 43-101 Standards of Disclosure for Mineral Projects (NI 43-101) by Norwest Corporation of Calgary, Alberta. It covers exploration so far on a portion of the Company’s leased areas (about 12,100 hectares [29,900 acres]).

Following Norwest's development of the mineral resource model, an in-place sand resource of commonly used frac sand size fractions in the tested area was calculated. A bulk density of 1.5 g/cm3 was used. Totaling 7,799 K Tonnes, (8,597 K Tons) the inferred mineral resource for each size fraction is: 20/40: 3,758 K Tonnes (4,142 K Tons); 40/70: 3,155 K Tonnes (3,478 K Tons); and 70/140: 886 K Tonnes (977 K Tons).

North America Frac Sand, Inc. (NAFS), closed Monday's trading session at $0.0165, down 10.81%, on 2,000 volume with 1 trade. The average volume for the last 60 days is 570,128 and the stock's 52-week low/high is $0.0081/$0.0949.

Propanc Biopharma, Inc. (PPCB)

Investing News and InvestorsHub reported on Propanc Biopharma, Inc. (PPCB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company headquartered in Camberwell, VIC 3124, Australia. It concentrates on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers. The Company has developed a formulation of anti-cancer compounds that exert several effects designed to control or prevent tumors from recurring and spreading throughout the body. Propanc Biopharma’s shares trade on the OTCQB.

The Company’s products involve or utilize pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, Propanc’s intention is to target patients with limited remaining therapeutic options for the treatment of solid tumors. In the future, its intention is to develop its lead product to treat early stage cancer and pre-cancerous diseases, and as a preventative measure for patients at risk of developing cancer based on genetic screening.

Propanc Biopharma is developing a long-term therapy founded on a pancreatic proenzyme formulation to prevent tumour recurrence and metastasis. The Company’s lead product, PRP, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is a solution for once daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen, for the treatment of pancreatic cancer.

Propanc (after wide-ranging laboratory research and a limited amount of human testing) has evidence that PRP reduces cancer cell growth through promotion of cell differentiation; enhances cell adhesion and may suppress metastasis progression; and has no serious side effects and improves patient survival.

Propanc Biopharma has received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the use of its lead product, PRP. The approved indication is one of the most lethal malignancies with a median survival of 6 months and a 5-year survival rate of under 5 percent.

Recent development progress for PRP includes successful completion of a GLP-compliant, 28-day repeat-dose toxicity study with no toxicological findings after administration. This indicates a broad safety margin and provides adequate data to support a safe starting dose for First-In-Human studies.

Propanc has established a four-year joint research partnership with the Jaén University, based in Andalucía, Spain. The main goal of the partnership is to expand Propanc Biopharma's product pipeline through discovering new compounds based on the mode of action of naturally derived proenzymes, trypsinogen and chymotrypsinogen that are the key active ingredients in Propanc’s lead product, PRP.

Propanc Biopharma, Inc. (PPCB), closed Monday's trading session at $0.42, down 6.67%, on 13,454 volume with 21 trades. The average volume for the last 60 days is 26,922 and the stock's 52-week low/high is $0.364/$5.00.


The QualityStocks
Company Corner


ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.9498, up 2.35%, on 43,564 volume with 46 trades. The stock’s average daily volume over the past 60 days is 52,203 and its 52-week low/high is $0.12/$2.75.

ChineseInvestors.com, Inc. today announces that its wholly owned subsidiary, ChineseHempOil.com, Inc., has established a Hemp Education Center in San Gabriel, California. The Company's club-style Hemp Education Center is at the center of San Gabriel's lively and growing Chinese-speaking community. Through its education center, ChineseHempOil.com, Inc. aims to provide valuable information to those that want to learn more about the potential health benefits of non-industrial hemp and hemp-derived CBD, while also increasing general awareness about non-industrial hemp which has roots in ancient Chinese medicine.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestors.com, Inc.'s Subsidiary Establishes Hemp Education Center in California

ChineseInvestors.com Featured in New Interview with SmallCapVoice.com

ChineseInvestors.com, Inc.'s Subsidiary Files Record of its First Hemp-Infused Skin Care Line With China FDA

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.047, up 34.29%, on 55,223,801 volume with 2,324 trades. The stock’s average daily volume over the past 60 days is 9,421,762, and its 52-week low/high is $0.0075/$0.142.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Discussing Public Companies Poised to Benefit from Rising Demand for Marijuana

SinglePoint Featured on MoneyTV with Donald Baillargeon, 7/14

NetworkNewsWire Announces Publication Discussing Emerging Standouts in the Legalized Marijuana Sector

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.51, up 10.87%, on 9,000 volume with 6 trades. The stock’s average daily volume over the past 60 days is 2,489, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Further Expands International Educational and Training Product Offerings with Purchase of Cranbury International

ProBility Media Corp. Enters into a Joint Venture with Industrial3D to Develop New Virtual Reality Products for Education and Training

ProBility Media Corp. Launches ProBility Safety Academy, an Online Security and Safety Training Institution

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.713, up 4.85%, on 81,102 volume with 36 trades. The stock’s average daily volume over the past 60 days is 35,764 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Introduces Fourth Medical Software Service Line, Continuing Rapid Expansion Strategy

ORHub, Inc. Executing Aggressive Expansion Strategy with Introduction of Third Service Line

ORHub, Inc. Signs National Deployment Agreement to Roll-out Transformative Medical Software in Major U.S. Markets

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.40465, up 1.42%, on 183,469 volume with 93 trades. The stock’s average daily volume over the past 60 days is 76,900 and its 52-week low/high is $0.0913/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication Highlighting the Operations of Several Public Cannabis-Biotech Companies

Lexaria Bioscience Technology Discussed by CFN Media Cannabis Industry Coverage

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is “One to Watch”


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Daily Trade Alert
(DVAX) +71.35%


Damn Good Penny Picks
(ACRL) +50.31%


(SING) +34.29%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251